

NOTARY CERTIFICATION

I, Theresa Papale Munro, a duly commissioned Notary Public for the Commonwealth of Pennsylvania, certify that the attached is a true and correct copy of the Priority Assignment for application(s) **63/505508** filed **01 June 2023** and **63/583600** filed **19 Sep 2023**, duly executed by the inventor(s) to **GlaxoSmithKline Intellectual Property (No.4) Limited**.



Notary Public

My Commission Expires: April 29, 2029

Dated: 18 November 2025

Commonwealth of Pennsylvania - Notary Seal
Theresa Papale Munro, Notary Public
Montgomery County
My commission expires April 29, 2029
Commission number 1249252
Member, Pennsylvania Association of Notaries



ASSIGNMENT

WHEREAS I/WE, **Michael P. DEMARTINO**, a citizen of the United States, of King of Prussia, PA, USA; and **Edward BRNARDIC**, a citizen of the Canada, of Landsdale, PA, USA (hereinafter called "the inventor(s)") have invented or discovered certain improvements in **Chemical Compounds and Uses Thereof** (hereinafter referred to as "the invention and improvements") for which a provisional application under 35 U.S.C. §111(b) was filed in the United States of America on **1 June 2023** under application number **63/505508**.

WHEREAS, GLAXOSMITHKLINE LLC, a company incorporated in the State of Delaware, USA, whose registered address is 251 Little Falls Drive, Wilmington, Delaware 19808, United States of America, is desirous of acquiring the whole right, title and interest in and to said invention and improvements, and in and to any applications for said invention and improvements, including the right to claim priority, and in and to any Letters Patent to be obtained therefor, in all countries, including the United States, its territories and possessions, and

WHEREAS GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED, a company incorporated in England whose registered address is 980 Great West Road, Brentford, Middlesex TW8 9GS, England, is desirous of acquiring from GLAXOSMITHKLINE LLC the whole right, title and interest in and to the invention and improvements and in and to the application, and

WHEREAS **GlaxoSmithKline Intellectual Property (No.4) Limited** a company incorporated in England whose registered address is GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, England, is desirous of acquiring the whole right, title and interest in and to the invention and improvements and in and to any applications for the invention and improvements and any Letters Patent to be obtained therefor, in all countries, including the United States of America, its territories and possessions;

NOW, THEREFORE, to all whom it may concern, be it known that I/we, the inventor(s), for good and valuable consideration unto me/us moving, the receipt whereof is hereby acknowledged, have sold, assigned and transferred, and by these presents do sell, assign and transfer my/our whole right, title and interest in and to said invention and improvements to said GLAXOSMITHKLINE LLC, throughout the United States of America, its territories and possessions, and in and to said application, and any extensions, reissues, continuations, continuations-in-part, and any divisions thereof, and in and to any and all Letters Patent of the United States of America, including any priority rights under the International Convention
AND, my/our whole right, title and interest in and to said invention and improvements to GLAXOSMITHKLINE LLC, in all other countries throughout the world, and in and to any applications in said

other countries, and continuations-in-part, patents of addition, revalidation patents, patents of importation, registrations, and any renewals, extensions and divisions thereof, and in and to any and all Letters Patent of said all other countries which may be granted on said invention and improvements including any priority rights under the International Convention.

GLAXOSMITHKLINE LLC in turn hereby assigns and transfers to GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED its whole right, title and interest in all countries, including the United States of America, its territories and possessions in and to the invention and improvements and in and to the application including the right to claim priority from the application in respect of any subsequent applications, and in and to any divisional application, continuation or continuation in part application thereof, and in and to any Supplementary Protection Certificate, extension or re-issue thereof, and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED in turn hereby assigns and transfers to **GlaxoSmithKline Intellectual Property (No.4) Limited** its whole right, title and interest in all countries, including the United States of America, its territories and possessions in and to the invention and improvements and in and to the application including the right to claim priority from the application in respect of any subsequent applications, and in and to any divisional application, continuation or continuation in part application thereof, and in and to any Supplementary Protection Certificate, extension or re-issue thereof

AND I/we the inventor(s) and GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED hereby authorise and request any patent arising therefrom, in all countries, including the United States of America, its territories and possessions, be issued to **GlaxoSmithKline Intellectual Property (No.4) Limited;**

AND GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED hereby, and I/we the inventor(s) for myself/ourselves and my/our respective executors and legal representatives hereby, agree at the request and cost of **GlaxoSmithKline Intellectual Property (No.4) Limited** to provide information and make execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in **GlaxoSmithKline Intellectual Property (No.4) Limited**, its successors and assigns, the whole right, title and interest in and to the invention and improvements and in and to the application hereby assigned and transferred in all countries, including the United States of America, its territories and possessions.

IN WITNESS whereof and with effect from 11 June 2021, the inventor(s) and the Attorney & Authorised Official of GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED


and **GlaxoSmithKline Intellectual Property (No.4) Limited** have hereunto set their respective hands.

Inventor Name

Signature

Date

Michael P. DEMARTINO:




May 10th, 2024

Edward BRNARDIC:



May 10th, 2024

SIGNED by Nicole Ginanni As the
Attorney & Authorised Official of GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE RESEARCH AND
DEVELOPMENT LIMITED and GlaxoSmithKline Intellectual Property (No.4) Limited:



Signature

Date: 05/21/2024

ASSIGNMENT

WHEREAS I/WE, **Edward BRNARDIC**, a citizen of the Canada, of Landsdale, PA, USA, **Kira Allyce CAMPBELL** a citizen of the United States, of Doylestown, PA, USA, **Michael P. DEMARTINO** a citizen of the United States, of King of Prussia, PA, USA, **Lara Kathryn LEISTER** a citizen of the United States, of Shillington, PA, USA, **Tessa LYNCH-COLAMETA** a citizen of the United States, of Philadelphia, PA, USA., **James P. PHELAN** a citizen of the United States, of Philadelphia, USA, **Michael D. VANHEYST** a citizen of the United States, of Harleysville, PA, USA, **Ann Marie ROWLEY** a citizen of the United States, of Phoenixville, PA, USA, **Amberly Breanna SANFORD** a citizen of the United States of, King of Prussia, PA, USA, **Hongyi YU** a citizen of the United States, of Wayne, PA, USA (hereinafter called "the inventor(s)") have invented or discovered certain improvements in **Chemical Compounds and Uses Thereof** (hereinafter referred to as "the invention and improvements") for which a provisional application under 35 U.S.C. §111(b) was filed in the United States of America on **19 September 2023** under application number **63/583,600**.

WHEREAS, GLAXOSMITHKLINE LLC, a company incorporated in the State of Delaware, USA, whose registered address is 251 Little Falls Drive, Wilmington, Delaware 19808, United States of America, is desirous of acquiring the whole right, title and interest in and to said invention and improvements, and in and to any applications for said invention and improvements, including the right to claim priority, and in and to any Letters Patent to be obtained therefor, in all countries, including the United States, its territories and possessions, and

WHEREAS GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED, a company incorporated in England whose registered address is 980 Great West Road, Brentford, Middlesex TW8 9GS, England, is desirous of acquiring from GLAXOSMITHKLINE LLC the whole right, title and interest in and to the invention and improvements and in and to the application, and

WHEREAS **GlaxoSmithKline Intellectual Property (No.4) Limited** a company incorporated in England whose registered address is GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, England, is desirous of acquiring the whole right, title and interest in and to the invention and improvements and in and to any applications for the invention and improvements and any Letters Patent to be obtained therefor, in all countries, including the United States of America, its territories and possessions;

NOW, THEREFORE, to all whom it may concern, be it known that I/we, the inventor(s), for good and valuable consideration unto me/us moving, the receipt whereof is hereby acknowledged, have sold, assigned and transferred, and by these presents do sell, assign and transfer my/our whole right, title and interest in

and to said invention and improvements to said GLAXOSMITHKLINE LLC, throughout the United States of America, its territories and possessions, and in and to said application, and any extensions, reissues, continuations, continuations-in-part, and any divisions thereof, and in and to any and all Letters Patent of the United States of America, including any priority rights under the International Convention

AND, my/our whole right, title and interest in and to said invention and improvements to GLAXOSMITHKLINE LLC, in all other countries throughout the world, and in and to any applications in said other countries, and continuations-in-part, patents of addition, revalidation patents, patents of importation, registrations, and any renewals, extensions and divisions thereof, and in and to any and all Letters Patent of said all other countries which may be granted on said invention and improvements including any priority rights under the International Convention.

GLAXOSMITHKLINE LLC in turn hereby assigns and transfers to GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED its whole right, title and interest in all countries, including the United States of America, its territories and possessions in and to the invention and improvements and in and to the application including the right to claim priority from the application in respect of any subsequent applications, and in and to any divisional application, continuation or continuation in part application thereof, and in and to any Supplementary Protection Certificate, extension or re-issue thereof, and GLAXOSMITHKLINE

RESEARCH AND DEVELOPMENT LIMITED in turn hereby assigns and transfers to **GlaxoSmithKline Intellectual Property (No.4) Limited** its whole right, title and interest in all countries, including the United States of America, its territories and possessions in and to the invention and improvements and in and to the application including the right to claim priority from the application in respect of any subsequent applications, and in and to any divisional application, continuation or continuation in part application thereof, and in and to any Supplementary Protection Certificate, extension or re-issue thereof

AND I/we the inventor(s) and GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED hereby authorise and request any patent arising therefrom, in all countries, including the United States of America, its territories and possessions, be issued to **GlaxoSmithKline Intellectual Property (No.4) Limited;**

AND GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED hereby, and I/we the inventor(s) for myself/ourselves and my/our respective executors and legal representatives hereby, agree at the request and cost of **GlaxoSmithKline Intellectual Property (No.4) Limited** to provide information and make execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in **GlaxoSmithKline Intellectual Property (No.4) Limited,**

its successors and assigns, the whole right, title and interest in and to the invention and improvements and in and to the application hereby assigned and transferred in all countries, including the United States of America, its territories and possessions.

IN WITNESS whereof and with effect from 11 June 2021, the inventor(s) and the Attorney & Authorised Official of GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED and **GlaxoSmithKline Intellectual Property (No.4) Limited** have hereunto set their respective hands.

Inventor Name

Signature

Date

Michael P. DEMARTINO:



May 10th, 2024

Kira Allyce CAMPBELL:

Edward BRNARDIC:



May 10th, 2024

Lara Kathryn LEISTER:

Tessa LYNCH-COLAMETA:

its successors and assigns, the whole right, title and interest in and to the invention and improvements and in and to the application hereby assigned and transferred in all countries, including the United States of America, its territories and possessions.

IN WITNESS whereof and with effect from 11 June 2021, the inventor(s) and the Attorney & Authorised Official of GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED and **GlaxoSmithKline Intellectual Property (No.4) Limited** have hereunto set their respective hands.

Inventor Name

Signature

Date

Michael P. DEMARTINO: _____

Kira Allyce CAMPBELL:

Kira Allyce Campbell

05-15-2024

Edward BRNARDIC:

Lara Kathryn LEISTER:

Lara Kathryn Leister

05-13-2024

Tessa LYNCH-COLAMETA:

Tessa Lynch-Colameta

5/14/2024


James P. PHELAN:

05/13/2024

Michael D. VANHEYST:

5/13/24


Ann Marie ROWLEY:

5/13/2024

Amberly Breanna SANFORD:

05/13/2024

Hongyi YU:

05-09-2024

SIGNED by Nicole Ginanni As the
Attorney & Authorised Official of GLAXOSMITHKLINE LLC and GLAXOSMITHKLINE RESEARCH AND
DEVELOPMENT LIMITED and GlaxoSmithKline Intellectual Property (No.4) Limited:



Signature

Date: 05/21/2024